MIF and neuroblastoma: An RNA-seq dataset (GSE62564) of 498 primary neuroblastoma samples, was used to evaluate the expression profiles of MIF, CXCL12, and the receptors CXCR4, CXCR2, CXCR7, CD74, and CD44, showed that MIF expression was highest in stage 4 high-risk tumors, while CXCR4 expression was lower in low-risk stage 4S tumor (206).